InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,195.83
(
0.29%
)
US TECH 100
17,664.80
(
0.31%
)
Dow Jones
38,920.87
(
0.18%
)
Brent Oil
83.54
(
0.07%
)
Bitcoin
63,493.30
(
0.52%
)
Post# of 251744
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 828
Posts 119584
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 171343

Tuesday, 06/17/2014 4:57:23 PM

Tuesday, June 17, 2014 4:57:23 PM

Post# of 251744
Notes from ENTA’s WF webcast:

• ABT-493 + (ABBV’s) ABT-530: Monotherapy cohorts in HCV patients are done; phase-2 combination study in HCV patients will start this summer.

• EDP-239: Monotherapy cohorts in HCV patients are almost done; phase-2 DDI trial with NVS’ alisporvir* in healthy volunteers starts 2Q14 (i.e. very soon); phase-2b trial of EDP-239 + alisporvir in HCV patients will start at conclusion of DDI trial, at which point ENTA will earn a $15M milestone payment from NVS.

*Cyclophilin inhibitor f/k/a DEB 025.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up